Clinical Trials
126 trialsStudy of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
LEAP-005
Merck Sharp & Dohme LLC
TraveraRTGx
Travera Inc
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Cue Biopharma
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
INOVOLINE
Hospices Civils de Lyon
PIPAC and FOLFOX for Gastric Cancer Peritoneal Cancer
Vilnius University
Study of ESG401 in Adults With Solid Tumors
Shanghai Escugen Biotechnology Co., Ltd
ARC-12
Arcus Biosciences, Inc.
EARN
Washington University School of Medicine
GLIMMER-01
Palleon Pharmaceuticals, Inc.
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
KEYVIBE-005
Merck Sharp & Dohme LLC
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
A Study of CDX-585 in Patients With Advanced Malignancies
Celldex Therapeutics
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
Genomic Testing and Resulting Medical Decisions
Arbeitsgemeinschaft medikamentoese Tumortherapie
PREFER
Labcorp Corporation of America Holdings, Inc
ACTolog
Immatics US, Inc.
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Zymeworks BC Inc.
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Stanford University
REMOVE
Lindis Bloodcare GmbH
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
BeiGene
ROOT
Taproot Health
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Acepodia Biotech, Inc.
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
HIPEC for Peritoneal Carcinomatosis
Albert Einstein College of Medicine
Dragon
Washington University School of Medicine
RADIANT
DxTerity Diagnostics
DUET-3
Xencor, Inc.
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Cancer Research and Biostatistics Clinical Trials Consortium
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
CAPABLE-IT
Istituti Clinici Scientifici Maugeri SpA
IPLUS
Seoul National University Bundang Hospital
PIPAC-nabpac
University Hospital, Ghent
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Celldex Therapeutics
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
DUET-4
Xencor, Inc.
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
DUET-2
Xencor, Inc.
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Exact Sciences Corporation
Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
Holy Name Medical Center, Inc.
DETECT
Boryung Pharmaceutical Co., Ltd
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
AbbVie